Pharsight

1. Caprelsa patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE42353	GENZYME CORP	Quinazoline derivatives and pharmaceutical compositions containing them	Jun, 2022 (1 year, 3 months ago)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8642608	GENZYME CORP	Quinazoline derivatives as VEGF inhibitors	Feb, 2022 (1 year, 7 months ago)
US8067427	GENZYME CORP	Pharmaceutical compositions comprising ZD6474	Aug, 2028 (4 years from now)

Drugs and Companies using VANDETANIB ingredient

Market Authorisation Date: 06 April, 2011

Treatment: For use in patients having symptomatic or progressive medullary thyroid cancer, with unresectable locally advanced or metastatic disease

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

CAPRELSA family patents

2. Cerdelga patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP16175117A	2020-05-14	Accord Healthcare Ltd	Granted and Under Opposition
EP16175117A	2020-05-14	Hetero Labs Limited	Granted and Under Opposition
EP16175117A	2020-05-13	Teva Pharmaceutical Industries Ltd	Granted and Under Opposition
EP10785289A	2015-02-27	SANDOZ AG	Patent maintained as amended

Patent	Proceeding Filing Date	Status	Respondent

US11458119	November, 2020	Decision	Hanlan Liu et al.
US10888547	April, 2019	Decision	Genzyme Corporation

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6916802	GENZYME CORP	Amino ceramide-like compounds and therapeutic methods of use	Apr, 2022 (1 year, 4 months ago)
US7196205	GENZYME CORP	Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors	Jun, 2026 (2 years from now)
US11458119	GENZYME CORP	Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase	Nov, 2030 (7 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7615573	GENZYME CORP	Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors	Apr, 2022 (1 year, 4 months ago)
US7253185	GENZYME CORP	Amino ceramide-like compounds and therapeutic methods of use	Apr, 2022 (1 year, 4 months ago)
US10888547	GENZYME CORP	Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase	Jan, 2031 (7 years from now)
US10888544	GENZYME CORP	Methods for treating Gaucher disease	Dec, 2038 (15 years from now)

Drugs and Companies using ELIGLUSTAT TARTRATE ingredient

Market Authorisation Date: 19 August, 2014

Treatment: Treatment of gaucher disease type 1; Long-term treatment of adults with gaucher disease type 1 who are cyp2d6 poor metabolizers with 84 mg once daily of eliglustat (equivalent to 100 mg of eliglustat ...

Dosage: CAPSULE;ORAL